Status:
WITHDRAWN
A Study to Compare the Experiences of Taking Daily Growth Hormone Injections to Weekly Ngenla in Children With Low Levels of Growth Hormone
Lead Sponsor:
Pfizer
Conditions:
Pediatric Growth Hormone Deficiency
Eligibility:
All Genders
3-16 years
Brief Summary
The purpose of this study is to learn about: * how children stick to taking their injections * their experience with the study medicines (Ngenla and daily growth hormone) prescribed to children with ...
Detailed Description
This multicenter, international, longitudinal, prospective, site-based, low-interventional study aims to evaluate and monitor treatment experience, defined by treatment adherence and persistence, in c...
Eligibility Criteria
Inclusion
- Children of any sex aged 3-16 years at baseline
- Children that have received a diagnosis of pGHD requiring GH injections.
- Children that are currently being treated (dGH/Ngenla) or are treatment naïve but ready to start treatment.
- Those who currently use a sharps bin to collect used needles \[as per normal standard of care (SoC)\].
Exclusion
- Children with psychosocial dwarfism.
- Children born small for gestational age (SGA)
- Children with chromosomal abnormalities
- Children with other causes of short stature, such as uncontrolled primary hypothyroidism or rickets.
- Children with a history of cancer.
- 7\. Children with other acute medical or psychiatric condition
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 17 2025
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06113952
Start Date
January 1 2024
End Date
October 17 2025
Last Update
February 9 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.